Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022.  

The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Monday, November 14, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13732765. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1569474&tp_key=bb26315c9c. Following the live webcast, an archived version of the call will be available on the website.

Monday November 14 @ 4:30 pm ET
Domestic: 1-877-407-0792
International: 1-201-689-8263
Conference ID: 13732765
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1569474&tp_key=bb26315c9c

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.

For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com

Staff

Recent Posts

SutheDermal.com Launches: Revolutionizing Comfort in Self-Injection Therapies

Revolutionary vibration device offers pain relief for finger pricks, GLP-1 shots, and wellness injections BOCA…

22 minutes ago

Delota Provides Corporate Update and Early Redemption of Convertible Debentures

Vaughan, Ontario--(Newsfile Corp. - April 22, 2025) - Delota Corp. (CSE: NIC) (FSE: S62) ("Delota"…

4 hours ago

Laxco, Inc. Announces the Launch of Accuva LEAP: A Revolutionary Imaging System Engineered for Tomorrow’s Research

MILL CREEK, Wash., April 22, 2025 /PRNewswire/ -- Laxco, Inc., a trailblazer in cutting-edge optical and…

6 hours ago

LABORATORY TECHNOLOGY EXPERT MAKES MAJOR ANNOUNCEMENT

Ryan El-Hosseiny to set the record straight Live TODAY in Miami Beach  MIAMI BEACH, Fla.,…

6 hours ago

Healthee raises $50M to redefine the future of health benefits

NEW YORK, April 22, 2025 /PRNewswire/ -- Healthee, the AI-powered platform transforming the health benefits experience,…

6 hours ago

Turacoz Group Drives Strategic Dialogue on Content Innovation at Reuters Events Pharma 2025 in Barcelona

UTRECHT, Netherlands, April 22, 2025 /PRNewswire/ -- At Reuters Events Pharma 2025 in Barcelona, industry leaders…

6 hours ago